NCT06865651 - Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

October 7, 2027

Conditions

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Interventions

DRUG

Remibrutinib

tablets

DRUG

Placebo

tablets

Trial Locations (17)

13353

RECRUITING

Novartis Investigative Site, Berlin

28006

RECRUITING

Novartis Investigative Site, Madrid

31008

RECRUITING

Novartis Investigative Site, Pamplona

33162

RECRUITING

Ziaderm Research LLC, North Miami Beach

34295

RECRUITING

Novartis Investigative Site, Montpellier

38043

RECRUITING

Novartis Investigative Site, Grenoble

55131

RECRUITING

Novartis Investigative Site, Mainz

60077

RECRUITING

Endeavor Health, Glenview

69495

RECRUITING

Novartis Investigative Site, Pierre-Bénite

72076

RECRUITING

Novartis Investigative Site, Tübingen

75970

RECRUITING

Novartis Investigative Site, Paris

01307

RECRUITING

Novartis Investigative Site, Dresden

61-731

RECRUITING

Novartis Investigative Site, Poznan

35 055

RECRUITING

Novartis Investigative Site, Rzeszów

02-962

RECRUITING

Novartis Investigative Site, Warsaw

08003

RECRUITING

Novartis Investigative Site, Barcelona

03010

RECRUITING

Novartis Investigative Site, Alicante